Lunai Bioworks Inc's Business Segments

Lunai Bioworks is a pre-clinical biotechnology company engaged in the development of cell, gene, and immunotherapy treatments using genetically modified cells aimed at cancer treatment. The company is currently in the discovery and pre-clinical development phases and has not generated revenue. Lunai Bioworks contracts third parties for product development and faces risks common to early-stage companies, including capital needs, potential treatment failures, and competitive challenges. Renovaro Cube and BioSymetrics are artificial intelligence-driven healthcare technology companies operating in rapidly evolving sectors with limited operating histories. Renovaro Cube transitioned from financial technology to cancer diagnostics in 2018 and currently has no commercial products or revenue from its cancer diagnostics AI platform. BioSymetrics has deployed a commercial AI-based biotechnology platform and has generated inconsistent revenues since 2017. Both companies have experienced net losses and expect to continue incurring losses. The registrant has encountered significant legal challenges, including lawsuits and regulatory investigations related to the arrest and conviction of co-founder Serhat Gümrükcü. These issues have adversely affected the company's reputation, operations, and financial condition, resulting in substantial legal expenses and potential ongoing negative impacts on business performance.

The company operates three reportable segments managed separately due to differing strategic and economic goals, technology, and marketing strategies: RENB, BioSymetrics, and RENC. RENB focuses on developing new immunotherapies for cancer treatment. BioSymetrics integrates multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to support biomarker discovery, therapeutic development, and precision medicine. RENC develops a predictive artificial intelligence-based diagnostic methodology aimed at earlier cancer detection. The chief executive officer serves as the chief operating decision maker, reviewing segment reports quarterly, assessing performance based on operating losses, and allocating resources accordingly. RENB and BioSymetrics operate in the United States, while RENC operates in the Netherlands. For the year ended June 30, 2025, segment operating losses were $15,530,056 for RENB, $237,880 for BioSymetrics, and $173,198,066 for RENC. Total consolidated assets were $1,907,647 for RENB, $6,109,643 for BioSymetrics, and $213,550 for RENC. The segments' accounting policies align with the company's overall policies.